The legal landscape surrounding the regulation of botanical ingredients in India has witnessed a significant development. As a Senior Advocate practicing before the High Courts and the Supreme Court of India, I find the recent intervention by the Hon’ble Karnataka High Court in the matter of Ashwagandha leaves to be a landmark moment for the nutraceutical and AYUSH industry. The court’s decision to stay the advisory issued by the Food Safety and Standards Authority of India (FSSAI) and the directive from the Ministry of AYUSH regarding the prohibition of Ashwagandha leaves in health supplements brings to the forefront the delicate balance between regulatory oversight and the right to carry on trade and business under Article 19(1)(g) of the Constitution of India.
This article provides an in-depth legal analysis of the case, the statutory framework governing health supplements, and the implications of the High Court’s interim order for stakeholders across the country. The core of the dispute lies in the interpretation of the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2016, and the subsequent administrative advisories that sought to override these regulations.
Understanding the Core of the Dispute: The Ashwagandha Controversy
Ashwagandha (Withania somnifera) is perhaps one of the most revered herbs in the Indian traditional medicine system, Ayurveda. While traditional texts have primarily focused on the use of the root of the plant, modern scientific research and industrial applications have expanded to include the use of its leaves, which contain specific withanolides beneficial for various health supplements. The conflict arose when the Ministry of AYUSH and subsequently the FSSAI issued advisories suggesting that the use of Ashwagandha leaves was not supported by traditional Ayurvedic texts and therefore should not be permitted in health supplements and nutraceuticals.
The petitioners, primarily manufacturing companies, challenged these directives on the grounds that they were contrary to the existing 2016 Regulations. Under these regulations, specifically at Sl. No. 432 of Schedule IV, “Ashwagandha” is listed as a permitted botanical ingredient. The petitioners argued that the term “Ashwagandha” in the schedule is used in its botanical sense, encompassing various parts of the plant, including the leaves, and is not restricted solely to the roots.
The Statutory Framework: The 2016 Regulations
To understand the legal weight of the Karnataka High Court’s stay, one must examine the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food and Novel Food) Regulations, 2016. These regulations were promulgated under the Food Safety and Standards Act, 2006, to provide a comprehensive legal framework for the burgeoning nutraceutical industry in India.
Schedule IV and Botanical Ingredients
Schedule IV of the 2016 Regulations provides a list of plant or botanical ingredients that are permitted for use in health supplements and nutraceuticals. At Serial Number 432, “Withania somnifera” or “Ashwagandha” is explicitly mentioned. The regulation does not specifically exclude leaves or limit the use to roots. For years, the industry operated on the understanding that as long as the botanical was listed in Schedule IV, its various parts could be utilized provided they met safety and quality standards.
The Primacy of Regulations over Advisories
From a legal standpoint, a regulation framed under a statute (subordinate legislation) holds higher legal sanctity than an administrative advisory or a circular. The petitioners argued that the FSSAI and the Ministry of AYUSH could not use an “advisory” to effectively amend or restrict the scope of a “Regulation.” If the authorities intended to ban the use of Ashwagandha leaves, the proper legal procedure would have been to amend the 2016 Regulations through the prescribed legislative process, rather than issuing a summary directive.
The Impugned Directives: Ministry of AYUSH and FSSAI
The controversy was sparked by a directive from the Ministry of AYUSH which stated that there is no substantial evidence in classical Ayurvedic texts to support the use of Ashwagandha leaves for therapeutic purposes. Following this, the FSSAI issued an advisory cautioning against the use of Ashwagandha leaves in food products and supplements, essentially directing manufacturers to cease production or reformulate their products.
The industry was caught off guard. Significant investments had been made in research, development, and manufacturing facilities based on the 2016 Regulations. The sudden prohibition via an advisory was seen as an arbitrary exercise of power, lacking scientific backing in the context of modern food science, even if traditional Ayurvedic texts remained silent on the use of leaves.
Legal Arguments Advanced by the Petitioners
Representing the manufacturers, the legal teams presented several compelling arguments before the Karnataka High Court. As a Senior Advocate, I observe that these arguments reflect fundamental principles of administrative law.
Violation of Natural Justice
The petitioners argued that the FSSAI and the Ministry of AYUSH failed to provide a pre-decisional hearing to the affected stakeholders. By issuing a blanket ban on the use of a previously permitted ingredient without consulting the industry or allowing for a transition period, the authorities violated the principles of natural justice.
Doctrine of Legitimate Expectation
Since the 2016 Regulations had included Ashwagandha in Schedule IV without specific restrictions on plant parts, the manufacturers had a “legitimate expectation” that they could continue to use the plant’s leaves in their formulations. Sudden policy reversals through non-statutory instruments are generally frowned upon by the Indian judiciary if they disrupt established business operations without a compelling public health emergency.
Scientific vs. Traditional Evidence
A major point of contention was the reliance on “traditional texts.” The petitioners argued that while Ayurveda is a vital guide, the FSSAI’s mandate under the 2006 Act is to regulate food based on modern scientific risk assessment. If scientific studies demonstrate that Ashwagandha leaves are safe for human consumption and provide nutritional value, the absence of their mention in ancient texts should not be a ground for a modern-day regulatory ban.
The Karnataka High Court’s Rationale for the Stay
The Hon’ble Karnataka High Court, after hearing the preliminary arguments, found a prima facie case in favor of the petitioners. The court’s decision to stay the operation of the advisory was based on three pillars of interlocutory relief: prima facie case, balance of convenience, and irreparable injury.
Prima Facie Case
The court noted that the 2016 Regulations are still in force and explicitly list Ashwagandha as a permitted ingredient. The question of whether “Ashwagandha” includes its leaves is a matter of interpretation that requires a detailed hearing. However, at first glance, an advisory cannot supersede a regulation.
Balance of Convenience
The balance of convenience weighed heavily in favor of the manufacturers. If the advisory were allowed to operate during the pendency of the litigation, companies would be forced to recall products, stop production lines, and suffer massive financial losses. Conversely, the authorities did not present immediate evidence of any health toxicity that necessitated an emergency ban.
Irreparable Injury
The court recognized that the sudden enforcement of the advisory would cause irreparable injury to the petitioners’ businesses, which could not be adequately compensated by money if the petitioners eventually won the case. The loss of market share and brand reputation in the global nutraceutical market was also a significant factor.
Broader Implications for the Nutraceutical Industry
This case is not just about Ashwagandha; it is about the regulatory environment for health supplements in India. The Karnataka High Court’s stay sends a strong signal to regulatory bodies regarding the limits of their administrative powers.
Consistency in Policy
For India to become a global hub for nutraceuticals, there must be consistency and predictability in policy. Frequent changes through “advisories” create an atmosphere of uncertainty that deters domestic and foreign investment. The industry requires a stable legal framework where changes are made through transparent, consultative, and evidence-based processes.
The Role of FSSAI as a Science-Based Regulator
The FSSAI is mandated to ensure “science-based standards” for articles of food. While traditional knowledge is an important data point, it should not be the sole criterion for banning ingredients that are widely accepted globally. This case highlights the need for the FSSAI to conduct its own independent scientific assessments rather than purely relying on directives from other ministries that may have different objectives.
Administrative Law Perspective: Delegation and Authority
From an administrative law perspective, this case touches upon the “Doctrine of Excessive Delegation” and the “Ultra Vires” rule. An administrative body created by a statute (like the FSSAI) must act within the four corners of that statute and the regulations framed thereunder. When an advisory seeks to take away a right granted by a regulation, it potentially acts “ultra vires” (beyond its powers).
In the Indian legal system, we have seen various instances where the judiciary has checked the “Executive” when it tries to legislate through circulars. The Karnataka High Court’s intervention is a continuation of this judicial trend to protect the “Rule of Law.”
Impact on International Trade and Exports
Ashwagandha is one of India’s largest herbal exports. Many Indian companies supply Ashwagandha leaf extracts to markets in the United States and Europe, where they are recognized as safe (GRAS) or permitted under specific supplement regulations. A domestic ban in India, even if based on “traditional non-use,” would have sent a negative signal to international regulators, potentially damaging the “Brand India” image in the global herbal market. The stay order helps maintain the status quo for exporters while the legalities are ironed out.
Future Course of Action: What Stakeholders Should Expect
While the stay is a significant temporary victory for the industry, the legal battle is far from over. The matter will now proceed to a final hearing where the FSSAI and the Ministry of AYUSH will file their detailed objections and scientific justifications.
Possibility of Regulatory Amendment
It is highly likely that the FSSAI may initiate a formal process to amend the 2016 Regulations to clarify the parts of the Ashwagandha plant that are permitted. If they follow the legislative route—issuing a draft amendment, inviting public comments, and then notifying the final change—the industry’s legal challenge regarding the “procedure” will become moot. However, the “scientific justification” for such a change would still be subject to judicial review.
Need for Industry Data
Manufacturers must use this interim period to compile robust scientific data regarding the safety and efficacy of Ashwagandha leaves. Clinical trials, toxicological studies, and historical usage data from other jurisdictions will be crucial in defending the continued use of this ingredient before the court and the regulator.
Conclusion: A Win for the Rule of Law
The Karnataka High Court’s decision to stay the FSSAI advisory and AYUSH directive on Ashwagandha leaves is a testament to the robustness of the Indian judicial system in protecting businesses from arbitrary administrative actions. As a Senior Advocate, I believe this case will serve as a precedent for how botanical ingredients are regulated in the future. It underscores the principle that while public health is paramount, regulatory actions must be grounded in law, guided by science, and implemented through fair and transparent procedures.
For now, the manufacturers can breathe a sigh of relief as their products containing Ashwagandha leaves, listed under Sl. No. 432 of Schedule IV, can remain on the shelves. However, the industry must remain vigilant and proactive in engaging with regulators to ensure that the eventual final ruling or subsequent amendments are balanced, fair, and conducive to the growth of the health supplement sector in India.
This litigation serves as a reminder that in the intersection of traditional wisdom and modern regulation, the law remains the ultimate arbiter, ensuring that progress is not stifled by administrative overreach.
